Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Abstrakt

The SAVOR-TIMI 53 trial supports the overall CV safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category. AEs and serious AEs as well as glycemic efficacy of saxagliptin in elderly patients are similar to those found in younger patients.

Klíčová slova

• type-2 diabetes-mellitus
• dipeptidyl peptidase-4 inhibitors
• placebo-controlled trial
• glycemic control
• elderly-patients
• clinical-trials
• cardiovascular-disease
• patient population
• pooled analysis
• double-blind